Arymo is a brand name for sumatriptan—a selective 5‑HT₁B/1D receptor agonist used to abort acute migraine attacks (with or without aura).
Below is a concise, evidence‑based overview of the drug, its generic counterpart, and key clinical information that can help you understand, prescribe, or discuss it with a healthcare professional.
---
1. Generic Form & Brand Variants
| Generic | Common Brand Names (U.S.) | Other Brand Names | Forms Available |
|---------|---------------------------|-------------------|-----------------|
| Sumatriptan | Arymo | Imitrex, Imitrex Rapid, Imitrex II | Oral tablet (50 mg, 100 mg), nasal spray, subcutaneous injection |
Note: In some countries (e.g., India, Brazil) Arymo itself is the brand name, but the generic is sumatriptan.
---
2. Mechanism of Action
- Agonist of 5‑HT₁B/1D receptors → induces vasoconstriction of cranial blood vessels, inhibits release of vasoactive neuropeptides from trigeminal nerves, and reduces pain signaling in the brainstem.
---
3. Indications
- Acute migraine headache (with or without aura)
Adults and adolescents ≥12 years
- Cluster headache (off‑label, evidence from case series)
---
4. Dosage & Administration
| Age / Weight | Standard Oral Dose | Repeat Dose | Max Daily Dose |
|--------------|--------------------|------------|----------------|
| ≥12 yrs (or > 50 kg) | 50 mg tablet (or 100 mg for severe migraine) | May repeat after ≥2 h | 100 mg (or 200 mg) in 24 h |
| 12‑17 yrs | 25 mg tablet | Repeat after 2 h | 50 mg in 24 h |
| 6‑11 yrs | 12.5 mg tablet | Repeat after 2 h | 25 mg in 24 h |
- Nasal Spray: 30 mg (two sprays) → repeat after 30 min if needed.
- Subcutaneous (SC) Injection: 6 mg → repeat after 2 h (max 12 mg in 24 h).
Tip: For patients with severe or persistent pain, start with 100 mg if available, as it yields a quicker response.
---
5. Contraindications
| Condition | Why |
|-----------|-----|
| Ischemic heart disease, uncontrolled hypertension, coronary artery disease, atherosclerosis, or vasospastic disorders | Sumatriptan’s vasoconstrictive effect can precipitate coronary ischemia or stroke. |
| History of stroke or transient ischemic attack (TIA) | Risk of recurrent cerebrovascular events. |
| Severe hepatic or renal impairment | Though sumatriptan is minimally metabolized, caution is advised. |
| Pregnancy category C (in animal studies) | Use only if benefits outweigh risks. |
Do not use if you’re taking another triptan, or any medication that can potentiate serotonin syndrome (e.g., SSRIs, SNRIs, MAOIs, St. John’s wort).
---
6. Common Adverse Effects
| Symptom | Frequency | Clinical Significance |
|---------|-----------|----------------------|
| Dizziness, fatigue, paresthesias, mild chest discomfort | 10‑30 % | Usually transient; monitor if chest pain. |
| Nausea, abdominal discomfort | 10‑15 % | Consider anti‑emetics. |
| Light‑headedness, fainting | <5 % | Avoid driving until effect wears off. |
| Rash, itching, urticaria | <5 % | Possible allergic reaction; stop if severe. |
| Sexual dysfunction (e.g., reduced libido) | Rare | Usually reversible. |
Severe reactions: Hypotension, seizures, or signs of serotonin syndrome (e.g., agitation, tremor, hyperreflexia) are rare but require immediate medical attention.
---
7. Drug Interactions
| Drug | Interaction | Practical Considerations |
|------|-------------|--------------------------|
| SSRIs/SNRIs | ↑Serotonin syndrome risk | Avoid combination or use at least 4–5 days apart. |
| MAOIs | ↑Serotonin syndrome risk | Contraindicated. |
| Triptan analogs (e.g., Rizatriptan) | Additive vasoconstriction